Advertisement
News
Advertisement

Meridia (sibutramine hydrochloride): Early Communication about an Ongoing Safety Review

Fri, 11/20/2009 - 1:50pm
FDA MedWatch
FDA is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading